Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes of trientine after d-penicillamine withdrawal in Wilson disease
2013-003564-31Phase 4Completed
- Sponsor
- Univar Solutions
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trientine in Wilson disease (WD), sponsored by Univar Solutions. Primary endpoint: Clinical course of hepatic disease. Started Oct 2013; status: completed.
02
Drugs
trientine
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2013-003564-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003564-31.